Psa capture agents, compositions, methods and preparation thereof

Abstract

Disclosed herein are novel synthetic prostate specific antigen (PSA)-targeted capture agents that specifically bind PSA. In certain embodiments, these PSA capture agents are biligand or triligand capture agents containing two or three target-binding moieties, respectively.

What is claimed is: 
     
         1 . A synthetic detection agent comprising a multi-ligand prostate specific antigen (PSA)-targeted capture agent that specifically binds PSA in serum. 
     
     
         2 . The detection agent of  claim 1 , wherein the capture agent is a cyclic triligand resistant to proteolytic digestion, wherein the cyclic triligand comprises an anchor ligand, a secondary ligand, and a tertiary ligand. 
     
     
         3 . The detection agent of  claim 1 , wherein the capture agent is stable in storage as a lyophilized powder. 
     
     
         4 . The detection agent of  claim 1 , wherein the capture agent is stable in storage at temperature of about −80° C. to about 40° C. 
     
     
         5 . The detection agent of  claim 1 , wherein the capture agent is stable in storage at room temperature. 
     
     
         6 . The detection agent of  claim 1 , wherein the capture agent is stable in human serum for at least 24 hours. 
     
     
         7 . The detection agent of  claim 1 , wherein the capture agent is stable at a pH in the range of (3.0-8.0). 
     
     
         8 . The detection agent of  claim 1 , wherein the capture agent is labeled with copper-DOTA. 
     
     
         9 . The detection agent of  claim 1 , wherein the capture agent is labeled with biotin. 
     
     
         10 . The detection agent of  claim 1 , wherein the capture agent binds to a non-canonical epitope on a protein. 
     
     
         11 . The detection agent of  claim 1 , wherein the capture agent is an immunotherapeutic. 
     
     
         12 . The detection agent of  claim 1 , wherein the capture agent is a diagnostic agent. 
     
     
         13 . The detection agent according to  claim 1 , wherein the linkage between one or more of the anchor ligand, secondary ligand, and tertiary ligand comprises a 1,5-substituted-1,2,3-triazole residue (Tz5) or a 1,4-substituted-1,2,3-triazole residue (Tz4): 
       
         
           
           
               
               
           
         
       
     
     
         14 . The detection agent according to  claim 2 , wherein the anchor ligand is a cyclic L-peptide, the secondary ligand is a D-peptide, and the tertiary ligand is a D-peptide. 
     
     
         15 . The detection agent according to  claim 2 , wherein the linkages between the anchor ligand and the secondary ligand and between the secondary ligand and the tertiary ligand comprise Tz5. 
     
     
         16 . The detection agent according to  claim 2 , comprising a structure selected from the group consisting of Tz4-triligand and Tz5-triligand: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         17 . A method of preparing the Tz5-triligand according to  claim 16  comprising:
 a) synthesizing side-chain-protected biotin-PEG 5 -CVFAHNYDYLVC (side-chain-protected biotin-PEG5 anchor synthetic block (I)), side-chain-protected Tz5-Gllffk (side-chain-protected secondary synthetic block (I)), and side-chain-protected Tz5-rrivk (side-chain-protected tertiary synthetic block (I)) having the following structures: 
 
       
         
           
           
               
               
           
         
         b) coupling the side-chain-protected biotin-PEG 5 anchor synthetic block (I) and the side-chain-protected secondary synthetic block (I) to form a side-chain protected biotin-PEG 5 -CVFAHNYDYLVC-Tz5-Gllffk (side-chain-protected biotin-PEG 5 -PSA Tz5-biligand synthetic block (I)) having the following structure: 
       
       
         
           
           
               
               
           
         
         c) coupling side-chain-protected biotin-PEG 5 -Tz5-biligand synthetic block (I) with the side-chain-protected tertiary synthetic block (I) to form side-chain-protected biotin-PEG 5 -CVFAHNYDYLVC-Tz5-Gllffk-Tz5-rrivk (side-chain protected Biotin-PEG 5 -PSA Tz5-triligand synthetic block (I)) having the following structure: 
       
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         d) deprotecting the side-chain-protected Biotin-PEG 5 -PSA Tz5-triligand synthetic block (I) to form biotin-PEG 5 -CVFAHNYDYLVC-Tz5-Gllffk-Tz5-rrivk; and 
         e) forming disulfide bond to provide biotin-PEG 5 -cyclic(CVFAHNYDYLVC)-Tz5-Gllffk-Tz5-rrivk (biotin-PEG 5 -PSA Tz5-triligand (I)) having the following structure: 
       
       
         
           
           
               
               
           
         
       
       wherein PEG 5  is —(NH—(C 2 H 4 —O—) 5 —C(O))—, Trt is trityl, Boc is tert-butyloxycarbonyl), and TFA is trifluoroacetic acid. 
     
     
         18 . A method of developing a PSA-targeted capture agent according to  claim 1  comprising the following steps:
 a) contacting PSA with biotin-PEG 5 -cyclic (CVFAHNYDYLVC)-Az4 (“azide-modified PSA-PCC anchor selection block (I)”) to provide a PSA-anchor complex; 
 b) contacting the PSA-anchor complex with a first plurality of candidate peptides to select a PSA-PCC secondary ligand, the peptides coupled with a D-propargylglycine at its N-terminus; 
 c) providing a PSA-PCC biligand by forming a 1,2,3-triazole linkage between the PSA-PCC anchor selection block and the PSA-PCC secondary ligand, wherein the azido and alkynyl group of the anchor selection block and the secondary ligand are brought in close proximity by binding to the target protein to provide a bead modified with the PSA-PCC biligand; 
 d) selecting the beads modified with the PSA-PCC biligand; 
 removing the PSA-PCC biligands from the beads modified with the PSA-PCC biligand; 
 e) sequencing the PSA-PCC secondary ligand of the PSA-PCC biligand; 
 f) preparing a biotin-PEG 5 -cyclic (CVFAHNYDYLVC)-PSA secondary ligand-Az4 (“azide-modified PCC biligand selection block (I)”); and 
 repeating steps of a) to f) until a PSA capture agent having desired antibody-like properties is screened; 
 
       wherein PEG 5  is —(NH—(C 2 H 4 —O—) 5 —C(O))— and Az4 is L-azidolysine. 
     
     
         19 . A method of detecting PSA using the PSA capture agent of  claim 1  in an immunoassay wherein the PSA capture agent replaces an antibody or its equivalent in the immunoassay. 
     
     
         20 . The method of  claim 19 , wherein the immunoassay is selected from the group of Western blot, pull-down assay, dot blot, and ELISA.